DCs transduced with MAGE-1 at an MOI of 100 showed limited toxicity and maximal production of MAGE-1 (data not shown). In this study, CCL3 and CCL20-recruited DCs were modified with a tumor antigen gene and

used as vaccines for an anti-tumor immune response ex vivo and in vivo. Ex vivo, when T cells were primed with MAGE-1-modified DCs and added to tumor cells, they were able to lyse tumor cells efficiently and specifically. High cytolytic activity in association with a Th1-type response could possibly contribute to the profound anti-tumor effects that we observed. In vivo, vaccination with CCL3 and CCL20-recruited DCs modified with MAGE-1 https://www.selleckchem.com/products/PF-2341066.html remarkably inhibited subcutaneous tumor growth and size. This observation suggests Selleckchem BAY 73-4506 the treatment potential of these cells as vaccines. In addition, splenic T cells obtained from mice vaccinated with DC-Ad-MAGE-1 produced high levels of IFN-γ and showed specific cytotoxic activity. By contrast, responses induced by nontransduced DCs and TAA-loaded DCs were far less potent. While most DC-based vaccination strategies target solid, non-metastatic tumors, our vaccination strategy employing TAA gene-modified DCs revealed efficacy against metastatic tumors as well. Future work will address the idea that this approach may be a viable one for treatment of gastric cancers in patients. Conclusion In this study,

we demonstrated that F4/80-B220-CD11c+ DC precursors were rapidly recruited into the peripheral blood by administration of CCL3 and FAD CCL20 in mice. This is essential for preparing DC-based vaccines against tumors. Importantly, vaccination with these DCs modified with MAGE-1, could elicit specific CTL responses to gastric cancer cells, and led to tumor rejection ex vivo and in vivo. These results suggest that an evaluation of this DC-based immunotherapy strategy for gastric cancer {Selleck Anti-diabetic Compound Library|Selleck Antidiabetic Compound Library|Selleck Anti-diabetic Compound Library|Selleck Antidiabetic Compound Library|Selleckchem Anti-diabetic Compound Library|Selleckchem Antidiabetic Compound Library|Selleckchem Anti-diabetic Compound Library|Selleckchem Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|Anti-diabetic Compound Library|Antidiabetic Compound Library|buy Anti-diabetic Compound Library|Anti-diabetic Compound Library ic50|Anti-diabetic Compound Library price|Anti-diabetic Compound Library cost|Anti-diabetic Compound Library solubility dmso|Anti-diabetic Compound Library purchase|Anti-diabetic Compound Library manufacturer|Anti-diabetic Compound Library research buy|Anti-diabetic Compound Library order|Anti-diabetic Compound Library mouse|Anti-diabetic Compound Library chemical structure|Anti-diabetic Compound Library mw|Anti-diabetic Compound Library molecular weight|Anti-diabetic Compound Library datasheet|Anti-diabetic Compound Library supplier|Anti-diabetic Compound Library in vitro|Anti-diabetic Compound Library cell line|Anti-diabetic Compound Library concentration|Anti-diabetic Compound Library nmr|Anti-diabetic Compound Library in vivo|Anti-diabetic Compound Library clinical trial|Anti-diabetic Compound Library cell assay|Anti-diabetic Compound Library screening|Anti-diabetic Compound Library high throughput|buy Antidiabetic Compound Library|Antidiabetic Compound Library ic50|Antidiabetic Compound Library price|Antidiabetic Compound Library cost|Antidiabetic Compound Library solubility dmso|Antidiabetic Compound Library purchase|Antidiabetic Compound Library manufacturer|Antidiabetic Compound Library research buy|Antidiabetic Compound Library order|Antidiabetic Compound Library chemical structure|Antidiabetic Compound Library datasheet|Antidiabetic Compound Library supplier|Antidiabetic Compound Library in vitro|Antidiabetic Compound Library cell line|Antidiabetic Compound Library concentration|Antidiabetic Compound Library clinical trial|Antidiabetic Compound Library cell assay|Antidiabetic Compound Library screening|Antidiabetic Compound Library high throughput|Anti-diabetic Compound high throughput screening| patients is an important next step. Acknowledgements This work was supported by the Scientific Research Foundation of Ministry of Public Health of China (No. WKJ20042011). References 1. Hohenberger P, Gretschel S: Gastric cancer. Lancet 2003, 362:305–15.PubMedCrossRef 2. Guida F, Formisano G,

Esposito D, Antonino A, Conte P, Bencivenga M, Persico M, Avallone U: Gastric cancer: surgical treatment and prognostic score. Minerva Chir 2008, 63:93–9.PubMed 3. Liakakos T, Fatourou E: Stage-specific guided adjuvant treatment for gastric cancer. Ann Surg Oncol 2008, 15:2622–3.PubMedCrossRef 4. Gilboa E: DC-based cancer vaccines. J Clin Invest 2007, 117:1195–203.PubMedCrossRef 5. Banchereau J, Steinman RM: Dendritic cells and the control of immunity. Nature 1998, 392:245–52.PubMedCrossRef 6. Zhang Y, Yoneyama H, Wang Y, Ishikawa S, Hashimoto S, Gao JL, Murphy P, Matsushima K: Mobilization of dendritic cell precursors into the circulation by administration of MIP-1α in mice. J Natl Cancer Inst 2004, 96:201–9.PubMedCrossRef 7.